Vir Biotechnology, Inc. Common Stock (VIR) Stock Price

VIRStock

$9.96+71.72%52W

Market Cap$1.69B

P/E—

PEG Ratio—

Div yield—

Beta1.78

VIR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-10.80%

Price vs S&P 500 (4W)-7.13%

VGM Score69.75

Book Value / Share (Quarterly)$5.81

P/TBV (Annual)1.11x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-65.12%

Cash Flow / Share (Quarterly)$-1.20

Price vs S&P 500 (YTD)53.25%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-41.54%

EPS (TTM)$-1.01

10-Day Avg Trading Volume2.31M

EPS Excl Extra (TTM)$-1.01

Revenue Growth (5Y)-2.14%

EPS (Annual)$-3.16

ROI (Annual)-57.23%

Gross Margin (Annual)99.96%

Net Profit Margin (5Y Avg)-395.16%

Cash / Share (Quarterly)$3.15

Revenue Growth QoQ (YoY)19582.54%

ROA (Last FY)-43.68%

Revenue Growth TTM (YoY)1496.08%

EBITD / Share (TTM)$-0.93

ROE (5Y Avg)-15.91%

Operating Margin (TTM)-48.77%

Cash Flow / Share (Annual)$-2.84

P/B Ratio1.72x

P/B Ratio (Quarterly)1.75x

Net Income / Employee (Annual)$-1,193,400

EV / Revenue (TTM)4.64x

Net Interest Coverage (TTM)10.09x

ROA (TTM)-11.68%

EV / EBITDA (TTM)1.68x

EPS Incl Extra (Annual)$-3.16

Current Ratio (Annual)5.54x

Quick Ratio (Quarterly)5.69x

3-Month Avg Trading Volume2.02M

52-Week Price Return71.72%

EV / Free Cash Flow (Annual)-2.40x

Revenue / Employee (TTM)$826,300

Tangible BV / Share (Quarterly)$5.76

P/S Ratio (Annual)24.58x

Asset Turnover (Annual)0.07x

52-Week High$12.00

Operating Margin (5Y Avg)-438.90%

EPS Excl Extra (Annual)$-3.16

CapEx CAGR (5Y)-5.76%

Tangible BV CAGR (5Y)2.09%

26-Week Price Return-0.90%

Quick Ratio (Annual)5.09x

13-Week Price Return5.62%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.04x

Enterprise Value$1.41B

Revenue / Share Growth (5Y)-5.04%

Asset Turnover (TTM)0.28x

Book Value / Share Growth (5Y)-0.50%

Revenue / Employee (Annual)$186,800

Pretax Margin (Annual)-638.56%

Cash / Share (Annual)$3.35

3-Month Return Std Dev50.37%

Gross Margin (5Y Avg)96.11%

Net Income / Employee (TTM)$-343,300

EBITDA Interim CAGR (5Y)4.16%

ROE (Last FY)-57.23%

Net Interest Coverage (Annual)11.83x

EPS Basic Excl Extra (Annual)$-3.16

P/FCF (TTM)13.67x

Receivables Turnover (TTM)4.18x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.01

Receivables Turnover (Annual)4.18x

ROI (TTM)-14.86%

P/S Ratio (TTM)5.56x

Pretax Margin (5Y Avg)-395.11%

Revenue / Share (Annual)$0.49

Tangible BV / Share (Annual)$5.43

Price vs S&P 500 (52W)56.19%

Year-to-Date Return65.17%

5-Day Price Return-11.86%

EPS Normalized (Annual)$-3.16

ROA (5Y Avg)-13.52%

Net Profit Margin (Annual)-638.87%

Month-to-Date Return-10.91%

Cash Flow / Share (TTM)$-4.36

EBITD / Share (Annual)$-3.46

Operating Margin (Annual)-699.18%

ROI (5Y Avg)-15.91%

EPS Basic Excl Extra (TTM)$-1.01

P/TBV (Quarterly)1.76x

P/B Ratio (Annual)1.10x

Pretax Margin (TTM)-41.47%

Book Value / Share (Annual)$5.49

Price vs S&P 500 (13W)2.94%

Beta1.78x

P/FCF (Annual)1.06x

Revenue / Share (TTM)$1.80

ROE (TTM)-14.86%

52-Week Low$4.82

vGradeB

gGradeB

mGradeB

vgmGradeB

VIR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$0.90	$0.47	-47.50%(-$0.43)
Q1 2026	May 6, 2026	$0.48	-$0.85	-276.62%(-$1.33)
Q4 2025	Feb 23, 2026	-$0.45	-$0.31	+31.57%(+$0.14)
Q3 2025	Nov 5, 2025	-$0.86	-$1.17	-35.98%(-$0.31)
Q2 2025	Aug 6, 2025	-$0.72	-$0.80	-11.38%(-$0.08)

VIR Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.21

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	B	168.6x	-19.0%	—	—	$17.17

About Vir Biotechnology, Inc. Common Stock

Vir Biotechnology is a clinical-stage biopharmaceutical company developing immunology-focused medicines for serious infectious diseases and cancer. The company leverages proprietary technologies including antibody engineering, an AI discovery platform (dAIsY), and a masking platform (PRO-XTEN) to develop a pipeline that includes therapies for hepatitis delta virus and HIV, as well as multiple solid tumor programs. Currently, the company generates revenue primarily through licensing agreements and research grants while advancing its clinical development programs.